Your session is about to expire
← Back to Search
Electronic Alert for Hypertension (ALERT-PA Trial)
N/A
Waitlist Available
Led By Jenifer M Brown, MD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
History of Atrial Fibrillation or Atrial Flutter (ICD Code)
Three or more current antihypertensive medication prescriptions
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
ALERT-PA Trial Summary
This trial aims to evaluate if a computer alert can increase screening and treatment of a common but overlooked cause of high blood pressure that carries risks.
Who is the study for?
This trial is for adults over 18 with high blood pressure, seen at certain clinics in the last 2 years. They must have a history of very high blood pressure readings or be on multiple blood pressure medications, have low potassium levels, or a history of specific heart rhythm problems. People already diagnosed with Primary Aldosteronism or those recently treated with certain drugs for it cannot join.Check my eligibility
What is being tested?
The study tests if an electronic alert system helps doctors screen patients for Primary Aldosteronism—a commonly missed cause of high blood pressure—more effectively. It checks whether this alert increases screening rates and leads to better specialist referrals and treatment options.See study design
What are the potential side effects?
Since the intervention involves only a computerized alert system to improve testing practices rather than direct patient treatments, there are no direct side effects from participating in this clinical trial.
ALERT-PA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have a history of Atrial Fibrillation or Atrial Flutter.
Select...
I am currently taking three or more medications for high blood pressure.
Select...
My potassium level is below 3.5 or I've been prescribed potassium supplements in the last 5 years.
ALERT-PA Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Frequency of PA testing orders by provider
Secondary outcome measures
Frequency of "Positive" PA results
Frequency of E-Consult order by provider
Frequency of Empiric Mineralocorticoid Receptor Antagonist (MRA) Prescription
+2 moreOther outcome measures
Change in Systolic Blood Pressure
ALERT-PA Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: BPA Alert InterventionExperimental Treatment1 Intervention
An on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the clinician that their patient should be screened for Primary Aldosteronism and provides an order set for the corresponding laboratory evaluation. Details of the electronic alert are provided in the Intervention description.
Group II: No Alert InterventionActive Control1 Intervention
No electronic alert will be issued in the No Intervention group. Providers will continue standard of care with their patients.
Find a Location
Who is running the clinical trial?
Brigham and Women's HospitalLead Sponsor
1,616 Previous Clinical Trials
11,469,348 Total Patients Enrolled
3 Trials studying Primary Aldosteronism
65 Patients Enrolled for Primary Aldosteronism
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,840 Previous Clinical Trials
47,850,524 Total Patients Enrolled
Jenifer M Brown, MDPrincipal InvestigatorBrigham and Women's Hospital
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 years old or older.I have a history of Atrial Fibrillation or Atrial Flutter.I am currently taking three or more medications for high blood pressure.I have a history of high blood pressure.Your blood pressure has been consistently high during visits to the doctor.I have seen a doctor at the specified clinic within the last 2 years.I have been prescribed an MRA in the last 3 months.I have been diagnosed with Primary Aldosteronism.My potassium level is below 3.5 or I've been prescribed potassium supplements in the last 5 years.
Research Study Groups:
This trial has the following groups:- Group 1: BPA Alert Intervention
- Group 2: No Alert Intervention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are participants still being enrolled for this research study?
"Clinicaltrials.gov has reported that, as of June 22nd 2023, this medical trial is not recruiting participants at present. Initially posted on October 1st 2023, the study is not currently open for enrolment; however, there are over 700 other clinical trials actively seeking patients right now."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger